IAA
KZR

Ironsides Asset Advisors’s Kezar Life Sciences KZR Stock Holding History

Ironsides Asset Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,092
Closed -$34.2K – 97
2023
Q1 		$34.2K Hold
1,092
– – 0.02% 90
2022
Q4 		$77K Hold
1,092
– – 0.04% 85
2022
Q3 		$94K Buy
1,092
+30
+3% +$2.92K 0.04% 81
2022
Q2 		$88K Sell
1,062
-40
-4% -$3.53K 0.03% 95
2022
Q1 		$183K Hold
1,102
– – 0.06% 93
2021
Q4 		$184K Sell
1,102
-5
-0.5% -$564 0.05% 90
2021
Q3 		$96K Sell
1,107
-574
-34% -$38K 0.03% 94
2021
Q2 		$91K Sell
1,681
-382
-19% -$21.7K 0.03% 99
2021
Q1 		$123K Buy
2,063
+30
+1% +$1.75K 0.04% 91
2020
Q4 		$106K Buy
2,033
+152
+8% +$8.46K 0.03% 80
2020
Q3 		$91K Buy
1,881
+281
+18% +$13.4K 0.03% 72
2020
Q2 		$83K Hold
1,600
– – 0.03% 77
2020
Q1 		$70K Buy
+1,600
New +$65.1K 0.04% 68
2019
Q4 		– Sell
-1,765
Closed -$58K – 94
2019
Q3 		$58K Hold
1,765
– – 0.02% 95
2019
Q2 		$136K Buy
1,765
+589
+50% +$91.6K 0.05% 93
2019
Q1 		$209K Buy
+1,176
New +$232K 0.07% 92

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ironsides Asset Advisors's KZR Position: Q2 2023 in Review

Ironsides Asset Advisors sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 1,092 shares — an estimated $34.2K sold.

Ironsides Asset Advisors first reported a position in KZR in Q1 2019 and held it in 16 quarters. The position peaked at $209K in Q1 2019. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Ironsides Asset Advisors reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Ironsides Asset Advisors sold 1,092 Kezar Life Sciences shares in Q2 2023, an estimated $34.2K.
  • Ironsides Asset Advisors first reported a position in Kezar Life Sciences in Q1 2019 and held it in 16 quarters.
  • Ironsides Asset Advisors's Kezar Life Sciences position peaked at $209K in Q1 2019.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Ironsides Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.